- Home
- AREN vs SLN Comparison
AREN vs SLN Comparison
Compare AREN & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AREN | SLN |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 300.9M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | AREN | SLN |
|---|---|---|
| Price | $1.05 | $10.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.00 | ★ $42.60 |
| AVG Volume (30 Days) | 113.8K | ★ 395.8K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 191.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,892,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 27.46 | N/A |
| 52 Week Low | $1.05 | $4.19 |
| 52 Week High | $7.85 | $10.21 |
Technical Indicators
Market Signals| Indicator | AREN | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 32.45 | 77.03 |
| Support Level | N/A | $5.87 |
| Resistance Level | $1.61 | N/A |
| Average True Range (ATR) | 0.13 | 0.73 |
| MACD | 0.02 | 0.41 |
| Stochastic Oscillator | 1.41 | 90.53 |
Price Performance
Historical ComparisonAbout AREN The Arena Group Holdings Inc.
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The company has four reportable segments: Sports & Leisure, Finance, Lifestyle, and Platform & Other. The company generates revenue from Sports & Leisure. Geographically, the company operates in United States; and Others. It generates maximum revenue from United States.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.